Hemab Therapeutics completes $346.7M IPO at $18/share, adopts anti-takeover defenses

Filed May 4, 2026 · Period ending May 4, 2026 · ~1 min read

Key Changes

• high

  Completed IPO of 19.3M shares at $18/share, raising $346.7M gross proceeds with full underwriter over-allotment exercised. Company now publicly traded.

  Item 8.01 verify on EDGAR →
• high

  Authorized common stock increased to 400M shares and 5M preferred shares, giving board flexibility for future capital raises or equity compensation without stockholder approval.

  Item 5.03 verify on EDGAR →
• high

  Implemented staggered board with three-year terms and 75% supermajority vote requirement to remove directors. Board vacancies filled only by existing directors, not stockholders.

  Item 5.03 verify on EDGAR →